SRM/MRM targeted proteomics as a tool for biomarker validation and absolute quantification in human urine

Expert Review of Molecular Diagnostics

Volumn 15, Issue 11, 2015, Pages 1441-1454

  Mermelekas, George ^a   Vlahou, Antonia ^a   Zoidakis, Jerome ^a  

^a BIOMEDICAL RESEARCH FOUNDATION   (Greece)

Author keywords

absolute quantification; biomarker validation; multiple reaction monitoring; selected reaction monitoring; targeted proteomics; urine

Indexed keywords

BIOLOGICAL MARKER; PROTEOME;

ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; IRRITABLE COLON; KIDNEY DISEASE; MALIGNANT NEOPLASTIC DISEASE; MASS SPECTROMETRY; MEDICAL INFORMATICS; MONITORING; MULTIPLE REACTION MONITORING; NONHUMAN; PROTEIN DEGRADATION; PROTEIN URINE LEVEL; PROTEOMICS; QUANTITATIVE ANALYSIS; REVIEW; SELECTED REACTION MONITORING; URINALYSIS; URINE; VALIDATION PROCESS; ANIMAL; PROCEDURES; REPRODUCIBILITY; STANDARDS; STATISTICAL ANALYSIS; WORKFLOW;

ANIMALS; BIOMARKERS; DATA INTERPRETATION, STATISTICAL; ENZYME-LINKED IMMUNOSORBENT ASSAY; HUMANS; MASS SPECTROMETRY; PROTEOME; PROTEOMICS; REPRODUCIBILITY OF RESULTS; WORKFLOW;

EID: 84947127997     PISSN: 14737159     EISSN: 17448352     Source Type: Journal    
DOI: 10.1586/14737159.2015.1093937     Document Type: Review

References (86)

1. Moodley N, Ngxamngxa U, Turzyniecka MJ, Pillay TS. Historical perspectives in clinical pathology: a history of glucose measurement. J Clin Pathol 2015; 68 (4): 258-64
2. Barratt J, Topham P. Urine proteomics: the present and future of measuring urinary protein components in disease. CMAJ 2007; 177 (4): 361-8
3. Kentsis A, Monigatti F, Dorff K, et al. Urine proteomics for profiling of human disease using high accuracy mass spectrometry. Proteom Clin App 2009; 3 (9): 1052-61
4. Adachi J, Kumar C, Zhang Y, et al. The human urinary proteome contains more than 1500 proteins, including a large proportion of membrane proteins. Genome Biol 2006; 7 (9): R80
5. Van De Vrie M, Deegens JK, Van Der Vlag J, Hilbrands LB. Effect of long-term storage of urine samples on measurement of kidney injury molecule 1 (KIM-1) and neutrophil gelatinase-associated lipocalin (NGAL). Am J Kidney Dis 2014; 63 (4): 573-6
6. Schaub S, Wilkins J, Weiler T, et al. Urine protein profiling with surface-enhanced laser-desorption/ionization time-of-flight mass spectrometry. Kidney Int 2004; 65 (1): 323-32
7. Theodorescu D, Wittke S, Ross MM, et al. Discovery and validation of new protein biomarkers for urothelial cancer: a prospective analysis. Lancet Oncol 2006; 7 (3): 230-40
8. Thomas CE, Sexton W, Benson K, et al. Urine collection and processing for protein biomarker discovery and quantification. Cancer Epidemiol Bio Preven 2010; 19 (4): 953-9
9. Decramer S, Gonzalez De Peredo A, Breuil B, et al. Urine in clinical proteomics. MCP 2008; 7 (10): 1850-62
10. Whiteaker JR, Zhao L, Anderson L, Paulovich AG. An automated and multiplexed method for high throughput peptide immunoaffinity enrichment and multiple reaction monitoring mass spectrometry-based quantification of protein biomarkers. MCP 2010; 9 (1): 184-96
11. Rosser CJ, Dai Y, Miyake M, et al. Simultaneous multi-analyte urinary protein assay for bladder cancer detection. BMC Biotechnol 2014; 14: 24
12. Chen LM, Chang M, Dai Y, et al. External validation of a multiplex urinary protein panel for the detection of bladder cancer in a multicenter cohort. Cancer Epidemiol Bio Preven 2014; 23 (9): 1804-12
13. Rosser CJ, Chang M, Dai Y, et al. Urinary protein biomarker panel for the detection of recurrent bladder cancer. Cancer Epidemiol Bio Preven 2014; 23 (7): 1340-5
14. Urquidi V, Kim J, Chang M, et al. CCL18 in a multiplex urine-based assay for the detection of bladder cancer. PLoS ONE 2012; 7 (5): e37797
15. Caiazzo RJ Jr, Orourke DJ, Barder TJ, et al. Native antigen fractionation protein microarrays for biomarker discovery. Methods Molec Biol 2011; 723: 129-48
16. Vaidya VS, Ferguson MA, Bonventre JV. Biomarkers of acute kidney injury. Annu Rev Pharmacol Toxicol 2008; 48: 463-93
17. Zoidakis J, Makridakis M, Zerefos PG, et al. Profilin 1 is a potential biomarker for bladder cancer aggressiveness. MCP 2012; 11 (4): M111 009449
18. Aebersold R, Burlingame AL, Bradshaw RA. Western blots versus selected reaction monitoring assays: time to turn the tables? MCP 2013; 12 (9): 2381-2
19. Picotti P, Aebersold R. Selected reaction monitoring-based proteomics: workflows, potential, pitfalls and future directions. Nat Methods 2012; 9 (6): 555-66
20. Nilsson T, Mann M, Aebersold R, et al. Mass spectrometry in high-throughput proteomics: ready for the big time. Nat Methods 2010; 7 (9): 681-5
21. Mallick P, Schirle M, Chen SS, et al. Computational prediction of proteotypic peptides for quantitative proteomics. Nat Biotechnol 2007; 25 (1): 125-31
22. Liebler DC, Zimmerman LJ. Targeted quantitation of proteins by mass spectrometry. Biochemistry 2013; 52 (22): 3797-806
23. Martens L, Hermjakob H, Jones P, et al. PRIDE: the proteomics identifications database. Proteomics 2005; 5 (13): 3537-45
24. Craig R, Cortens JP, Beavis RC. Open source system for analyzing, validating, and storing protein identification data. J Proteome Res 2004; 3 (6): 1234-42
25. Deutsch EW, Lam H, Aebersold R. PeptideAtlas: a resource for target selection for emerging targeted proteomics workflows. EMBO Rep 2008; 9 (5): 429-34
26. Peptide Atlas. Available from: www.peptideatlas.org
27. Khristenko N, Domon B. Quantification of proteins in urine samples using targeted mass spectrometry methods. Methods molec Biol 2015; 1243: 207-20
28. Keshishian H, Addona T, Burgess M, et al. Quantitative, multiplexed assays for low abundance proteins in plasma by targeted mass spectrometry and stable isotope dilution. MCP 2007; 6 (12): 2212-29
29. Rost H, Malmstrom L, Aebersold R. A computational tool to detect and avoid redundancy in selected reaction monitoring. MCP 2012; 11 (8): 540-9
30. Elliott P, Peakman TC, Biobank UK. The UK Biobank sample handling and storage protocol for the collection, processing and archiving of human blood and urine. Int J Epidemiol 2008; 37 (2): 234-44
31. Mischak H, Kolch W, Aivaliotis M, et al. Comprehensive human urine standards for comparability and standardization in clinical proteome analysis. Proteomics. Clin App 2010; 4 (4): 464-78
32. Court M, Selevsek N, Matondo M, et al. Toward a standardized urine proteome analysis methodology. Proteomics 2011; 11 (6): 1160-71
33. Chen YT, Chen HW, Domanski D, et al. Multiplexed quantification of 63 proteins in human urine by multiple reaction monitoring-based mass spectrometry for discovery of potential bladder cancer biomarkers. J Proteomics 2012; 75 (12): 3529-45
34. Selevsek N, Matondo M, Sanchez Carbayo M, et al. Systematic quantification of peptides/proteins in urine using selected reaction monitoring. Proteomics 2011; 11 (6): 1135-47
35. Available from: www.hukpp.org
36. Available from: www.eurokup.org
37. Available from: https://brendanx-uw1.gs.washington.edu/labkey/project/home/software/Skyline
38. Maclean B, Tomazela DM, Shulman N, et al. Skyline: an open source document editor for creating and analyzing targeted proteomics experiments. Bioinformatics 2010; 26 (7): 966-8
39. Mead JA, Bianco L, Ottone V, et al. MRMaid, the web-based tool for designing multiple reaction monitoring (MRM) transitions. Mol Cell Proteom 2009; 8 (4): 696-705
40. Brusniak MY, Kwok ST, Christiansen M, et al. ATAQS: A computational software tool for high throughput transition optimization and validation for selected reaction monitoring mass spectrometry. BMC Bioinformatics 2011; 12: 78
41. Oberg AL, Vitek O. Statistical design of quantitative mass spectrometry-based proteomic experiments. J Proteome Res 2009; 8 (5): 2144-56
42. Kall L, Vitek O. Computational mass spectrometry-based proteomics. PLOS Comput Biol 2011; 7 (12): e1002277
43. Halsey LG, Curran-Everett D, Vowler SL, Drummond GB. The fickle P value generates irreproducible results. Nat Methods 2015; 12 (3): 179-85
44. Choi M, Chang CY, Clough T, et al. MSstats: an R package for statistical analysis of quantitative mass spectrometry-based proteomic experiments. Bioinformatics 2014; 30 (17): 2524-6
45. Available from: www.msstats.org
46. Bioconductor. Available from: www.bioconductor.org
47. Jemal A, Bray F, Center MM, et al. Global cancer statistics. CA Cancer J Clin 2011; 61 (2): 69-90
48. Huttenhain R, Soste M, Selevsek N, et al. Reproducible quantification of cancer-associated proteins in body fluids using targeted proteomics. Sci Transl Med 2012; 4 (142): 142ra194
49. Polanski M, Anderson NL. A list of candidate cancer biomarkers for targeted proteomics. Biomark Insights 2007; 1: 1-48
50. Chuang CK, Liao SK. Differential expression of CD44 variant isoforms by cell lines and tissue specimens of transitional cell carcinomas. Anticancer Res 2003; 23 (6C): 4635-9
51. Miyake H, Gleave M, Kamidono S, Hara I. Overexpression of clusterin in transitional cell carcinoma of the bladder is related to disease progression and recurrence. Urology 2002; 59 (1): 150-4
52. Osman I, Bajorin DF, Sun TT, et al. Novel blood biomarkers of human urinary bladder cancer. Clin Can Res 2006; 12 (11 Pt 1): 3374-80
53. Kageyama S, Isono T, Matsuda S, et al. Urinary calreticulin in the diagnosis of bladder urothelial carcinoma. Inter J Urol 2009; 16 (5): 481-6
54. Chen CL, Lai YF, Tang P, et al. Comparative and targeted proteomic analyses of urinary microparticles from bladder cancer and hernia patients. J Proteome Res 2012; 11 (12): 5611-29
55. Geisler C, Gaisa NT, Pfister D, et al. Identification and Validation of Potential New Biomarkers for Prostate Cancer Diagnosis and Prognosis Using 2D-DIGE and MS. BioMed Res Inter 2015; 2015: 454256
56. Laderach DJ, Gentilini LD, Giribaldi L, et al. A unique galectin signature in human prostate cancer progression suggests galectin-1 as a key target for treatment of advanced disease. Cancer Res 2013; 73 (1): 86-96
57. Bhavsar T, Mccue P, Birbe R. Molecular diagnosis of prostate cancer: are we up to age? Semin Oncol 2013; 40 (3): 259-75
58. Shi T, Gao Y, Quek SI, et al. A highly sensitive targeted mass spectrometric assay for quantification of AGR2 protein in human urine and serum. J Proteome Res 2014; 13 (2): 875-82
59. Shi T, Fillmore TL, Sun X, et al. Antibody-free, targeted mass-spectrometric approach for quantification of proteins at low picogram per milliliter levels in human plasma/serum. Proc Nat Acad Sci USA 2012; 109 (38): 15395-400
60. Marks LS, Bostwick DG. Prostate Cancer Specificity of PCA3 Gene Testing: Examples from Clinical Practice. Rev Urol 2008; 10 (3): 175-81
61. Sir Elkhatim R, Li JY, Yong TY, Gleadle JM. Dipping your feet in the water: podocytes in urine. Expert Rev Mol Diagn 2014; 14 (4): 423-37
62. Rood IM, Deegens JK, Merchant ML, et al. Comparison of three methods for isolation of urinary microvesicles to identify biomarkers of nephrotic syndrome. Kidney Int 2010; 78 (8): 810-16
63. Zubiri I, Posada-Ayala M, Sanz-Maroto A, et al. Diabetic nephropathy induces changes in the proteome of human urinary exosomes as revealed by label-free comparative analysis. J Proteomics 2014; 96: 92-102
64. Gomes MB, Nogueira VG. Acute-phase proteins and microalbuminuria among patients with type 2 diabetes. Diabetes Res Clin Pract 2004; 66 (1): 31-9
65. Jin J, Ku YH, Kim Y, et al. Differential proteome profiling using iTRAQ in microalbuminuric and normoalbuminuric type 2 diabetic patients. Exp Diabetes Res 2012; 2012: 168602
66. Kim K, Kim SJ, Yu HG, et al. Verification of biomarkers for diabetic retinopathy by multiple reaction monitoring. J Proteome Res 2010; 9 (2): 689-99
67. Manwaring V, Heywood WE, Clayton R, et al. The identification of new biomarkers for identifying and monitoring kidney disease and their translation into a rapid mass spectrometry-based test: evidence of presymptomatic kidney disease in pediatric Fabry and type-I diabetic patients. J Proteome Res 2013; 12 (5): 2013-21
68. Kestenbaum B, De Boer IH. Urine albumin-to-creatinine ratio: whats in a number? JASN 2010; 21 (8): 1243-4
69. Beasley-Green A, Burris NM, Bunk DM, Phinney KW. Multiplexed LC-MS/MS assay for urine albumin. J Proteome Res 2014; 13 (9): 3930-9
70. Martin H. Laboratory measurement of urine albumin and urine total protein in screening for proteinuria in chronic kidney disease. Clin Biochemist 2011; 32 (2): 97-102
71. Miller WG, Bruns DE, Hortin GL, et al. Current issues in measurement and reporting of urinary albumin excretion. Clin Chem 2009; 55 (1): 24-38
72. Zhang H, Liu Q, Zimmerman LJ, et al. Methods for peptide and protein quantitation by liquid chromatography-multiple reaction monitoring mass spectrometry. Molecular & cellular proteomics: MCP 2011; 10 (6): M110 006593
73. Mirzaei H, Mcbee JK, Watts J, Aebersold R. Comparative evaluation of current peptide production platforms used in absolute quantification in proteomics. Molecular & cellular proteomics: MCP 2008; 7 (4): 813-23
74. Lemoine J, Fortin T, Salvador A, et al. The current status of clinical proteomics and the use of MRM and MRM(3) for biomarker validation. Expert Rev Mol Diagn 2012; 12 (4): 333-42
75. Jaffuel A, Lemoine J, Aubert C, et al. Optimization of liquid chromatography-multiple reaction monitoring cubed mass spectrometry assay for protein quantification: application to aquaporin-2 water channel in human urine. J Chromatog 2013; 1301: 122-30
76. Simon R, Lemoine J, Fonbonne C, et al. Absolute quantification of podocin, a potential biomarker of glomerular injury in human urine, by liquid chromatography-multiple reaction monitoring cubed mass spectrometry. J Pharm Biomed Anal 2014; 94: 84-91
77. Goo YA, Cain K, Jarrett M, et al. Urinary proteome analysis of irritable bowel syndrome (IBS) symptom subgroups. J Proteome Res 2012; 11 (12): 5650-62
78. Panchaud A, Scherl A, Shaffer SA, et al. Precursor acquisition independent from ion count: how to dive deeper into the proteomics ocean. Anal Chem 2009; 81 (15): 6481-8
79. Kondo T. Inconvenient truth: cancer biomarker development by using proteomics. Biochim Biophys Acta 2014; 1844 (5): 861-5
80. Li XJ, Hayward C, Fong PY, et al. A blood-based proteomic classifier for the molecular characterization of pulmonary nodules. Sci Transl Med 2013; 5 (207): 207ra142
81. Makawita S, Diamandis EP. The bottleneck in the cancer biomarker pipeline and protein quantification through mass spectrometry-based approaches: current strategies for candidate verification. Clin Chem 2010; 56 (2): 212-22
82. Hirayama A, Igarashi K, Tomita M, Soga T. Development of quantitative method for determination of gamma-glutamyl peptides by capillary electrophoresis tandem mass spectrometry: an efficient approach avoiding matrix effect. J chromatog 2014; 1369: 161-9
83. Sun L, Li Y, Champion MM, et al. Capillary zone electrophoresis-multiple reaction monitoring from 100 pg of RAW 264.7 cell lysate digest. The Analyst 2013; 138 (11): 3181-8
84. Stalmach A, Albalat A, Mullen W, Mischak H. Recent advances in capillary electrophoresis coupled to mass spectrometry for clinical proteomic applications. Electrophoresis 2013; 34 (11): 1452-64
85. Pontillo C, Filip S, Borras DM, et al. CE-MS-based proteomics in biomarker discovery and clinical application. Proteomics. Clin Application 2015
86. Liu X, Jin Z, Obrien R, et al. Constrained selected reaction monitoring: quantification of selected post-translational modifications and protein isoforms. Methods 2013; 61 (3): 304-12